Daiichi Sankyo
Daiichi Sankyo works on 10 rare diseases tracked on Trial Friend, including Adrenocortical Carcinoma, Cholangiocarcinoma, Duchenne Muscular Dystrophy and 7 more, with 3 active clinical trials (1 recruiting).
Daiichi Sankyo is a Japanese pharmaceutical company with roots dating back to 1899 (formed through the 2005 merger of Daiichi Pharmaceutical and Sankyo). The company is a global leader in antibody-drug conjugates for oncology, with programs touching rare cancers such as adrenocortical carcinoma and hereditary diffuse gastric cancer.
Focus areas at Daiichi Sankyo
Within its broader pharmaceutical portfolio, Daiichi Sankyo has active clinical trial programs and drug development efforts across 10 rare diseases, including Adrenocortical Carcinoma, Cholangiocarcinoma, Duchenne Muscular Dystrophy, Fibrodysplasia Ossificans Progressiva, Gastrointestinal Stromal Tumor, and 5 additional rare conditions. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows active and recruiting rare disease studies sponsored by Daiichi Sankyo, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Daiichi Sankyo is headquartered in Tokyo, Japan, founded in 2005, publicly traded under the ticker symbol 4568. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Daiichi Sankyo Drug Pipeline
Daiichi Sankyo has 3 active clinical trials across 2 development stages, with 1 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline counts the active and recruiting trials listed on this page, from ClinicalTrials.gov. For companies that work outside rare disease, we list only trials for rare diseases we track, so the company's full pipeline may be larger.
Daiichi Sankyo Clinical Trials (3)
Active and recruiting clinical trials sponsored by Daiichi Sankyo, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Daiichi Sankyo. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Adrenocortical Carcinoma. Turn any of these off from the link in every email.
FDA-Approved Drugs
Daiichi Sankyo Trial Locations
Daiichi Sankyo clinical trials are running at 30 sites in 4 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (10)
Diseases targeted by Daiichi Sankyo's clinical trial and drug development programs
Adrenocortical carcinoma is a rare, aggressive cancer of the adrenal cortex, the outer layer of the adrenal glands that sit on top of each kidney. These glands produce essential hormones including cor...
Cholangiocarcinoma is a rare and aggressive cancer that forms in the bile ducts, the thin tubes that carry digestive fluid (bile) from the liver to the small intestine. It can occur inside the liver (...
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginning in early childhood. The defective dystrophin protein normally protects muscl...
Fibrodysplasia Ossificans Progressiva (FOP) is an extremely rare genetic disorder characterized by progressive heterotopic ossification, where soft tissues (muscles, tendons, ligaments) gradually tran...
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, arising from the interstitial cells of Cajal or their precursors. Most GISTs are driven by...
Hereditary diffuse gastric cancer is an autosomal dominant cancer predisposition syndrome caused by germline CDH1 mutations. Nearly all carriers develop diffuse gastric cancer by age 80 if not treated...
Patient Resources
Organizations and resources related to Daiichi Sankyo's rare disease focus areas
Frequently Asked Questions About Daiichi Sankyo
Common questions about Daiichi Sankyo's rare disease programs, clinical trials, and treatments.